In this webinar, you will learn:

  • Workflows for antibody characterization that extend beyond the primary amino acid sequence
  • How to leverage HDX-MS for epitope mapping and SPR for binding kinetics to understand the mechanism of action and maximize the effectiveness of your characterization efforts
  • How to ensure high-quality antibody production with in-depth post-translational modification analysis and sequence variant analysis
  • About maintaining product purity and regulatory compliance with host-cell protein analysis

Abstract

Overlooking the intricacies of antibody characterization beyond the antibody sequence leads to unanticipated challenges during downstream development and IND submissions. Potential concerns may emerge related to production quality, including post-translational modifications (PTMs), sequence variants, and cell culture contaminants. As such, in-depth antibody characterization is best conducted early and often in the developmental pipeline.

What are the necessary steps to ensure the development of high-quality antibodies?  

The initial steps involve elucidating the primary amino acid sequence of the antibody, pinpointing its binding site on the antigen, as well as its binding kinetics. Prior to advancing to preclinical testing, it is essential to assess the quality and purity of the generated antibodies. This often entails PTM and in-depth glycan analysis, identifying sequence variants, and conducting host-cell protein analysis.

In this webinar, we explore mass spectrometry-based techniques designed for complete antibody characterization. We walk through a streamlined workflow for total antibody characterization, which includes understanding the structure and function of the antibody, to evaluating the overall quality of antibody production. 

Speaker Bios

Like this article? Get more.

Get notified of new content

Learn about upcoming webinars, new articles and special promotions.

Follow us on Linkedin

Great content, plus a little fun.

Rapid Novor

Biotechnology Research · Kitchener, Ontario · 5K followers · 51-200 employees

Talk to Our Scientists.

We Have Sequenced 9000+ Antibodies and We Are Eager to Help You.

Through next generation protein sequencing, Rapid Novor enables reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and developed the first recombinant polyclonal antibody diagnostics.

Talk to Our Scientists.

We Have Sequenced 9000+ Antibodies and We Are Eager to Help You.

Through next generation protein sequencing, Rapid Novor enables timely and reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and ran the first recombinant polyclonal antibody diagnostics

Talk to our scientists. We have sequenced over 9000+ antibodies and we are eager to help you.